Nature Reviews Rheumatology - Table of Contents alert Volume 11 Issue 12

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
December 2015 Volume 11 Number 12
Impact Factor 9.845 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Biosimilars in rheumatology: current perspectives and lessons learnt Thomas Dörner & Jonathan Kay
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Therapy: HSCT—resetting immune tolerance by boosting TREG cell diversity Published online: 03 November 2015 p681 | doi:10.1038/nrrheum.2015.149 PDF Connective tissue diseases: New low disease activity target defined in SLE Published online: 27 October 2015 p682 | doi:10.1038/nrrheum.2015.146 PDF Vasculitis syndromes: PR3 on apoptotic cells promotes inflammation in GPA Published online: 20 October 2015 p683 | doi:10.1038/nrrheum.2015.144 PDF Osteoarthritis: Autophagy prevents age-related OA Published online: 20 October 2015 p683 | doi:10.1038/nrrheum.2015.145 PDF Connective tissue diseases: ApoER2 linked to pregnancy complications in APS Published online: 03 November 2015 p684 | doi:10.1038/nrrheum.2015.150 PDF Rheumatoid arthritis: Novel NFκB inhibitor associated with RA severity Published online: 10 November 2015 p684 | doi:10.1038/nrrheum.2015.152 PDF IN BRIEF Rheumatoid arthritis: OPERA regimen gives excellent RA control (NCT00660647) | Genetics: New GWAS data link aberrant immunoregulation to SLE | Osteoarthritis: RCT supports TKR in eligible patients with osteoarthritis | Spondyloarthritis: Suboptimal monitoring of comorbidities in spondyloarthritis PDF
NEWS AND VIEWS		Top
Connective tissue diseases: Functional MRI in SLE—the current state Anselm Mak & Sen Hee Tay Published online: 20 October 2015 p686 | doi:10.1038/nrrheum.2015.143 Functional MRI (fMRI) is increasingly used in efforts to unravel the neuropathological processes of neuropsychiatric systemic lupus erythematosus (NPSLE). Standardization of scan protocols, imaging expertise and disease-related confounders of neuronal activities remain major challenges to the use of fMRI in the diagnosis and prognosis of NPSLE. Full Text | PDF | Supplementary information
Rheumatoid arthritis: Autoantibodies, citrullinated histones and initiation of synovitis Kevin D. Deane Published online: 29 September 2015 p688 | doi:10.1038/nrrheum.2015.134 In the development of rheumatoid arthritis, which factors govern the transition from systemic autoimmunity to synovitis? A study combining findings from human disease and animal models suggests that autoantibodies to neutrophil-derived citrullinated histone 2B are important for this transition; however, a 'second hit' involving intra-articular inflammation and citrullination could also be crucial to this process. Full Text | PDF
Clinical guidelines: Addressing comorbidities in systemic inflammatory disorders Tristan Boyd & Arthur Kavanaugh Published online: 22 September 2015 p689 | doi:10.1038/nrrheum.2015.129 Comorbidities affect outcomes and treatment decisions in patients with immune-driven systemic inflammatory disorders. New recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis and psoriatic arthritis might help optimize the management of these diseases and improve patient outcomes, but several considerations are relevant to their clinical implementation. Full Text | PDF
REVIEWS		Top
Cardiovascular comorbidity in rheumatic diseases Michael T. Nurmohamed, Maaike Heslinga & George D. Kitas Published online: 18 August 2015 p693 | doi:10.1038/nrrheum.2015.112 The burden of cardiovascular disease is high in patients with inflammatory joint disease, owing to the presence of inflammation and traditional cardiovascular risk factors. Current management of cardiovascular risk factors and control of disease activity are unsatisfactory, and patients could benefit from improvements in screening and coordination between the cardiology and rheumatology branches of health care. Abstract | Full Text | PDF
Patient-reported outcomes in core domain sets for rheumatic diseases Lilian H. D. van Tuyl & Maarten Boers Published online: 01 September 2015 p705 | doi:10.1038/nrrheum.2015.116 Most core sets of outcomes in rheumatology include some patient-reported outcomes (PROs), most commonly pain, function, and patient global assessment of disease activity. According to van Tuyl and Boers, further research is needed to understand the value of the patient assessment and to define how these three key PROs contribute to the broader concept of health-related quality of life. Abstract | Full Text | PDF
Biosimilars in rheumatology: current perspectives and lessons learnt Thomas Dörner & Jonathan Kay Published online: 18 August 2015 p713 | doi:10.1038/nrrheum.2015.110 The increasing use of biosimilars in the context of rheumatic diseases has been met with several challenges unique to this type of drugs. In this Review, Dörner and Kay describe the fast adoption of biosimilar agents worldwide, highlighting the different approaches to regulation implemented by national and supranational health care policy-makers. Issues such as extrapolation of indications and the definition of strategies for adequate postmarketing pharmacovigilance are also discussed. Abstract | Full Text | PDF
Mechanisms of crystal formation in gout—a structural approach Eliseo Pascual, Lia Addadi, Mariano Andrés & Francisca Sivera Published online: 15 September 2015 p725 | doi:10.1038/nrrheum.2015.125 Gout is caused by the precipitation of monosodium urate monohydrate (MSU) crystals in the joints and in other tissues. Although direct observations of MSU crystals as they form on tissues are lacking, morphological findings and comparison with the physiological process of biomineralization suggests possible mechanisms of pathological MSU crystal formation and the conditions that might favour the nucleation and growth of crystals at particular anatomical sites. Abstract | Full Text | PDF | Supplementary information
PERSPECTIVES		Top
OPINION 'MHC-I-opathy'—unified concept for spondyloarthritis and Behçet disease Dennis McGonagle, Sibel Zehra Aydin, Ahmet Gül, Alfred Mahr & Haner Direskeneli Published online: 03 November 2015 p731 | doi:10.1038/nrrheum.2015.147 This article presents the concept that Behçet disease and several spondyloarthropathies might have a common immunopathogenetic basis. The authors propose that barrier dysfunction in environmentally exposed organs, and aberrant innate immune reactions at sites of mechanical stress, trigger secondary adaptive immune CD8+ T-cell responses characterized by prominent neutrophilic inflammation. The differential immunopathology of these 'MHC-I-opathies' could reflect antigenic differences in target tissues. Abstract | Full Text | PDF
Advertisement
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2014. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.